OBJECTIVE: Recent advances in neural engineering have restored mobility to people with paralysis, relieved symptoms of movement disorders, reduced chronic pain, restored the sense of hearing, and provided sensory perception to individuals with sensory deficits. APPROACH: This progress was enabled by the team-based, interdisciplinary approaches used by neural engineers. Neural engineers have advanced clinical frontiers by leveraging tools and discoveries in quantitative and biological sciences and through collaborations between engineering, science, and medicine. The movement toward bioelectronic medicines, where neuromodulation aims to supplement or replace pharmaceuticals to treat chronic medical conditions such as high blood pressure, diabetes and psychiatric disorders is a prime example of a new frontier made possible by neural engineering. Although one of the major goals in neural engineering is to develop technology for clinical applications, this technology may also offer unique opportunities to gain insight into how biological systems operate. MAIN RESULTS: Despite significant technological progress, a number of ethical and strategic questions remain unexplored. Addressing these questions will accelerate technology development to address unmet needs. The future of these devices extends far beyond treatment of neurological impairments, including potential human augmentation applications. Our task, as neural engineers, is to push technology forward at the intersection of disciplines, while responsibly considering the readiness to transition this technology outside of the laboratory to consumer products. SIGNIFICANCE: This article aims to highlight the current state of the neural engineering field, its links with other engineering and science disciplines, and the challenges and opportunities ahead. The goal of this article is to foster new ideas for innovative applications in neurotechnology.
OBJECTIVE: Recent advances in neural engineering have restored mobility to people with paralysis, relieved symptoms of movement disorders, reduced chronic pain, restored the sense of hearing, and provided sensory perception to individuals with sensory deficits. APPROACH: This progress was enabled by the team-based, interdisciplinary approaches used by neural engineers. Neural engineers have advanced clinical frontiers by leveraging tools and discoveries in quantitative and biological sciences and through collaborations between engineering, science, and medicine. The movement toward bioelectronic medicines, where neuromodulation aims to supplement or replace pharmaceuticals to treat chronic medical conditions such as high blood pressure, diabetes and psychiatric disorders is a prime example of a new frontier made possible by neural engineering. Although one of the major goals in neural engineering is to develop technology for clinical applications, this technology may also offer unique opportunities to gain insight into how biological systems operate. MAIN RESULTS: Despite significant technological progress, a number of ethical and strategic questions remain unexplored. Addressing these questions will accelerate technology development to address unmet needs. The future of these devices extends far beyond treatment of neurological impairments, including potential human augmentation applications. Our task, as neural engineers, is to push technology forward at the intersection of disciplines, while responsibly considering the readiness to transition this technology outside of the laboratory to consumer products. SIGNIFICANCE: This article aims to highlight the current state of the neural engineering field, its links with other engineering and science disciplines, and the challenges and opportunities ahead. The goal of this article is to foster new ideas for innovative applications in neurotechnology.
Authors: E Budman; W Deeb; D Martinez-Ramirez; J G Pilitsis; Z Peng-Chen; M S Okun; A Ramirez-Zamora Journal: Eur J Neurol Date: 2018-02-01 Impact factor: 6.089
Authors: Andreas Kupsch; Reiner Benecke; Jörg Müller; Thomas Trottenberg; Gerd-Helge Schneider; Werner Poewe; Wilhelm Eisner; Alexander Wolters; Jan-Uwe Müller; Günther Deuschl; Marcus O Pinsker; Inger Marie Skogseid; Geir Ketil Roeste; Juliane Vollmer-Haase; Angela Brentrup; Martin Krause; Volker Tronnier; Alfons Schnitzler; Jürgen Voges; Guido Nikkhah; Jan Vesper; Markus Naumann; Jens Volkmann Journal: N Engl J Med Date: 2006-11-09 Impact factor: 91.245
Authors: Eric B Geller; Tara L Skarpaas; Robert E Gross; Robert R Goodman; Gregory L Barkley; Carl W Bazil; Michael J Berg; Gregory K Bergey; Sydney S Cash; Andrew J Cole; Robert B Duckrow; Jonathan C Edwards; Stephan Eisenschenk; James Fessler; Nathan B Fountain; Alicia M Goldman; Ryder P Gwinn; Christianne Heck; Aamar Herekar; Lawrence J Hirsch; Barbara C Jobst; David King-Stephens; Douglas R Labar; James W Leiphart; W Richard Marsh; Kimford J Meador; Eli M Mizrahi; Anthony M Murro; Dileep R Nair; Katherine H Noe; Yong D Park; Paul A Rutecki; Vicenta Salanova; Raj D Sheth; Donald C Shields; Christopher Skidmore; Michael C Smith; David C Spencer; Shraddha Srinivasan; William Tatum; Paul C Van Ness; David G Vossler; Robert E Wharen; Gregory A Worrell; Daniel Yoshor; Richard S Zimmerman; Kathy Cicora; Felice T Sun; Martha J Morrell Journal: Epilepsia Date: 2017-04-11 Impact factor: 5.864
Authors: Evon S Ereifej; Youjun Li; Monika Goss-Varley; Youjoung Kim; Seth M Meade; Keying Chen; Jacob Rayyan; He Feng; Keith Dona; Justin McMahon; Dawn Taylor; Jeffrey R Capadona; Jiayang Sun Journal: Micromachines (Basel) Date: 2020-09-03 Impact factor: 2.891